A retrospective cohort study to determine risk of selected AESIs following vaccination with BNT162b2 in immunocompromised, comorbidities, prior COVID-19 infection, pregnant individuals compared to unvaccinated subjects in Europe
Latest Information Update: 27 Sep 2022
At a glance
- Drugs Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Sep 2022 New trial record
- 28 Aug 2022 First results presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management